These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3693582)

  • 1. Influence of hepatic dysfunction on the pharmacokinetics of propafenone.
    Lee JT; Yee YG; Dorian P; Kates RE
    J Clin Pharmacol; 1987; 27(5):384-9. PubMed ID: 3693582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of an extemporaneous suspension of propafenone made from tablets.
    Olguín HJ; Pérez CF; Pérez JF; Mendiola BR; Portugal MC; Chávez JB
    Biopharm Drug Dispos; 2006 Jul; 27(5):241-5. PubMed ID: 16586461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic transport of indocyanine green in dogs chronically intoxicated with dimethylnitrosamine.
    Kawasaki S; Umekita N; Beppu T; Wada T; Sugiyama Y; Iga T; Hanano M
    Toxicol Appl Pharmacol; 1984 Sep; 75(2):309-17. PubMed ID: 6474462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodialysis removal of propafenone.
    Burgess ED; Duff HJ
    Pharmacotherapy; 1989; 9(5):331-3. PubMed ID: 2813154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between warfarin and propafenone in healthy volunteer subjects.
    Kates RE; Yee YG; Kirsten EB
    Clin Pharmacol Ther; 1987 Sep; 42(3):305-11. PubMed ID: 3621785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue distribution of propafenone in the rat after intravenous administration.
    Fernández J; Lligoña L; Puigdemont A; Guitart R; Riu JL; Arboix M
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):23-7. PubMed ID: 1936057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigations on the pharmacokinetics of propafenone in man.
    Hollmann M; Brode E; Hotz D; Kaumeier S; Kehrhahn OH
    Arzneimittelforschung; 1983; 33(5):763-70. PubMed ID: 6683556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
    Trenk D; Wagner F; Sachs W; Jähnchen E
    Eur J Clin Pharmacol; 1989; 37(3):313-6. PubMed ID: 2612546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propafenone kinetics in the horse. Comparative analysis of compartmental and noncompartmental models.
    Puigdemont A; Riu JL; Guitart R; Arboix M
    J Pharmacol Methods; 1990 Apr; 23(2):79-85. PubMed ID: 2332982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism for the abnormal liver scan in acute alcoholic liver injury.
    Hoefs JC; Green G; Reynolds TB; Sakimura I
    Am J Gastroenterol; 1984 Dec; 79(12):950-8. PubMed ID: 6507421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of portacaval shunt on drug disposition in patients with cirrhosis.
    Pomier-Layrargues G; Huet PM; Villeneuve JP; Marleau D
    Gastroenterology; 1986 Jul; 91(1):163-7. PubMed ID: 3710065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
    Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
    Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.
    Huet PM; Lelorier J
    Clin Pharmacol Ther; 1980 Aug; 28(2):208-15. PubMed ID: 7398188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlinear kinetics of propafenone metabolites in healthy man.
    Vozeh S; Haefeli W; Ha HR; Vlcek J; Follath F
    Eur J Clin Pharmacol; 1990; 38(5):509-13. PubMed ID: 2379537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of buccal absorption of propafenone single oral loading dose in healthy humans.
    Sasaki S; Koumi S; Sato R; Murata M; Nagasawa K; Sakurai E; Hikichi N; Hayakawa H
    Gen Pharmacol; 1998 Oct; 31(4):589-91. PubMed ID: 9792220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propafenone disposition during continuous venovenous hemofiltration.
    Seto W; Trope AE; Gow RM
    Ann Pharmacother; 1999 Sep; 33(9):957-9. PubMed ID: 10492500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of propafenone enantiomers in rats.
    Mehvar R
    Drug Metab Dispos; 1990; 18(6):987-91. PubMed ID: 1981549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.